SEER
Biotechnology · Healthcare
Chief Accounting Officer, CFO
2026-10-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Seer, Inc. publishes a filing, an earnings call transcript or a press release.
Get SEER alertsCharles Endweiss is recorded as Chief Accounting Officer and CFO at Seer, Inc. (SEER) since October 1, 2026. Seer, Inc. reported in an 8-K filed September 18, 2026 that Charles Endweiss was appointed principal financial officer, effective October 1, 2026. Seer, Inc. reported in an 8-K filed September 18, 2026 that Charles Endweiss was appointed principal accounting officer, effective October 1, 2026. Seer, Inc. reported in an 8-K filed September 18, 2026 that Charles Endweiss was appointed Treasurer, effective October 1, 2026. Charles Endweiss has spoken on 1 earnings call across 1 company, most recently for Seer, Inc. on November 10, 2026. Seer, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Seer, Inc. includes Omid Farokhzad (CEO and Board Member), Elona Kogan (General Counsel), David Hallal (Board Member) and 7 others.
“Mr. Endweiss will also serve as the principal financial officer and principal accounting officer of the Company as such terms are used for purposes of the rules and regulations of the Securities and Exchange Commission.”
“Mr. Endweiss will also serve as the principal financial officer and principal accounting officer of the Company as such terms are used for purposes of the rules and regulations of the Securities and Exchange Commission.”
“Total revenue for the third quarter of 2026 was $4.0 million, compared with $3.1 million in the second quarter. The sequential increase was driven by higher product revenue from increased instrument shipments and new customer agreements.”
SEC 8-K
2026-10-01–present
2026-10-01–present
2026-10-01–present
SEER
Biotechnology · Healthcare
Chief Accounting Officer, CFO
2026-10-01–present